TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3728269

Group type: EXPERIMENTAL
Intervention: Mexiletine treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Holter criteria I
Number of subjects: 30

Group type: COMPARATOR
Intervention: Holter criteria II
Number of subjects: 30

Group type: COMPARATOR
Intervention: Holter criteria III
Number of subjects: 30

Group type: COMPARATOR
Intervention: PES vs Holter I
Number of subjects: 30

Group type: COMPARATOR
Intervention: PES vs Holter II
Number of subjects: 30

Group type: COMPARATOR
Intervention: PES vs Holter III
Number of subjects: 30
Study: 29444414

Group type: EXPERIMENTAL
Intervention: Caffeine (4.8 ± 0.4 mg/kg body mass)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Beetroot juice (7.3 mmol of nitrate)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Caffeine placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: Beetroot juice placebo
Number of subjects: 9
Study: 27221313

Group type: EXPERIMENTAL
Intervention: Inclined head position during HS-WBRT using VMAT
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inclined head position
Number of subjects: 8
Study: 23963103

Group type: EXPERIMENTAL
Intervention: Gradual tract dilation with Alken metal dilators
Number of subjects: 66

Group type: COMPARATOR
Intervention: One-stage tract dilation
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups (Gradual and One-stage)
Number of subjects: 66
Study: 23225450

Group type: EXPERIMENTAL
Intervention: Temsirolimus and bevacizumab combination (arm A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sunitinib (arm B)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Interferon-alfa and bevacizumab (arm C)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Overall patient group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Response group
Number of subjects: 70
Study: 20019628

Group type: EXPERIMENTAL
Intervention: Perceived neighborhood safety
Number of subjects: 890

Group type: EXPERIMENTAL
Intervention: Perceived availability of places to walk
Number of subjects: 890

Group type: EXPERIMENTAL
Intervention: Proximity to school
Number of subjects: 890

Group type: EXPERIMENTAL
Intervention: Active destinations in neighborhood
Number of subjects: 890

Group type: EXPERIMENTAL
Intervention: Smaller-sized blocks
Number of subjects: 890

Group type: EXPERIMENTAL
Intervention: Demographic factors (race)
Number of subjects: 890
Study: 19029412

Group type: EXPERIMENTAL
Intervention: CA 19-9 levels lower than 180
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: CA 19-9 levels lower than or equal to 90
Number of subjects: 385
Study: 15277322

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 11342423

Group type: EXPERIMENTAL
Intervention: Rasburicase
Number of subjects: 52

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 52
Study: 9107160

Group type: EXPERIMENTAL
Intervention: Carvedilol with exercise training
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Propranolol with exercise training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sedentary patients treated with carvedilol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sedentary patients treated with propranolol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Trained patients (both carvedilol and propranolol)
Number of subjects: 23
Study: 8198025

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg twice daily, starting 2 weeks before PTCA and continuing after successful PTCA until follow-up angiography at 26 +/- 2 weeks.
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg twice daily
Number of subjects: 730
Study: 3147048

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low dose theophylline (5-10 mg/l)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Medium dose theophylline (10-15 mg/l)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High dose theophylline (15-20 mg/l)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Theophylline (all doses)
Number of subjects: 38
Study: 30123528

Group type: EXPERIMENTAL
Intervention: Reduced strength lager
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular strength lager
Number of subjects: 0
Study: 27350068

Group type: EXPERIMENTAL
Intervention: Tabalumab 100 mg + Dexamethasone 20 mg/day + Bortezomib 1.3 mg/m² (Cohort 1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tabalumab 300 mg + Dexamethasone 20 mg/day + Bortezomib 1.3 mg/m² (Cohort 2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combined treatment (Tabalumab 100 mg or 300 mg + Dexamethasone + Bortezomib)
Number of subjects: 16
Study: 26276751

Group type: EXPERIMENTAL
Intervention: Soy bread (34 mg isoflavones/slice)
Number of subjects: 32
Study: 22976766

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with imiglucerase
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12
Study: 20685535

Group type: EXPERIMENTAL
Intervention: Fluoride-releasing filled enamel sealant (Pro Seal)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Unfilled nonfluoride control (Transbond MIP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison of Pro Seal vs Transbond MIP
Number of subjects: 18
Study: 18346503

Group type: EXPERIMENTAL
Intervention: DASH intervention
Number of subjects: 57

Group type: COMPARATOR
Intervention: Routine outpatient hospital-based nutrition care (RC)
Number of subjects: 57
Study: 17182989

Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Cefotetan
Number of subjects: 1002
Study: 12800782

Group type: EXPERIMENTAL
Intervention: Nasal CPAP treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-controlled treatment trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 0
Study: 10742349

Group type: EXPERIMENTAL
Intervention: Literacy promoting intervention (developmentally appropriate children's books and educational materials)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Literacy promoting intervention
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control (no books or materials relevant to literacy)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control
Number of subjects: 205
Study: 8876022

Group type: EXPERIMENTAL
Intervention: Overnight abstinence
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Recent smoking
Number of subjects: 49

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 49
Study: 1557507

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2862032

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined atracurium and vecuronium
Number of subjects: 0
Study: 31809622

Group type: EXPERIMENTAL
Intervention: Androgen receptor splice variant 7 (AR‐V7) mRNA expression in hormone-sensitive prostate cancer (HSPC) and castration-resistant prostate cancer (CRPC)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: AR‐FL, AR‐V7, ARv567es, AR‐V3 mRNA expression
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: AR‐V7/AR‐FL ratio after ADT
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Neuroendocrine differentiation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Gleason score
Number of subjects: 19
Study: 29405668

Group type: EXPERIMENTAL
Intervention: Meloxicam (10 mg in 10 mL saline)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (10 mL)
Number of subjects: 80
Study: 25952561

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (including cognitive group sessions and individual sessions) with biweekly telephone follow-up for 3 months
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (intervention group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: General multidisciplinary MS rehabilitation (both groups)
Number of subjects: 120
Study: 24337625

Group type: EXPERIMENTAL
Intervention: CIK treatment plus standard treatment
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 132
Study: 22361751

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 30
Study: 20823097

Group type: EXPERIMENTAL
Intervention: Rolofylline 30 mg administered as a 4 h infusion
Number of subjects: 59
Study: 17588242

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BoNT‐B) 200 U or more
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BoNT‐B) 400 U
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BoNT‐B) 800 U
Number of subjects: 19
Study: 14762357

Group type: EXPERIMENTAL
Intervention: 100% fraction of inspired oxygen
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 14
Study: 11443569

Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500‐mg tablet twice daily for 3 days
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 9640487

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate plus clarithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omeprazole plus clarithromycin
Number of subjects: 0
Study: 8113836

Group type: EXPERIMENTAL
Intervention: Positive CSF cytocentrifuge examination with blast cells and normal CSF WBC count
Number of subjects: 64

Group type: COMPARATOR
Intervention: No blasts in CSF
Number of subjects: 64
Study: 3259976

Group type: EXPERIMENTAL
Intervention: Afferent stimulation (TENS/vibration)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pain relief scale and numerical rating scale
Number of subjects: 80
Study: 31728675

Group type: EXPERIMENTAL
Intervention: Single standard dose of sucrose 2 min before heel prick
Number of subjects: 72

Group type: COMPARATOR
Intervention: Double dose of sucrose 2 min before and 30 s after heel prick
Number of subjects: 72
Study: 29705116

Group type: EXPERIMENTAL
Intervention: Oxygen environment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nasal cannula
Number of subjects: 25
Study: 27312122

Group type: EXPERIMENTAL
Intervention: Oral product alone (ZO-1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral product with topical product (ZO-2 + ZT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Combination active groups (ZO-2 + ZT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Dietary supplement alone (ZO-1)
Number of subjects: 31
Study: 25615425

Group type: EXPERIMENTAL
Intervention: Facebook usage (10 minutes)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Magazine website (10 minutes)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Appearance-neutral control website (10 minutes)
Number of subjects: 112
Study: 24121608

Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Both ACB and FNB
Number of subjects: 54
Study: 21906549

Group type: EXPERIMENTAL
Intervention: Special screening and educational intervention (SI)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Control intervention (CI)
Number of subjects: 501
Study: 18754720

Group type: EXPERIMENTAL
Intervention: Prophylactic low-level laser therapy (LLLT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo light treatment
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Therapeutic low-level laser therapy (LLLT)
Number of subjects: 22
Study: 17056950

Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg IV
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg IV
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saline IV (Placebo)
Number of subjects: 75
Study: 14616463

Group type: EXPERIMENTAL
Intervention: Cranberry juice (500 mL diluted with 1500 mL tap water for 2 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tap water (2000 mL for 2 weeks)
Number of subjects: 20
Study: 16344024

Group type: EXPERIMENTAL
Intervention: 5 mg of oxymorphone immediate release (IR)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 10450717

Group type: EXPERIMENTAL
Intervention: Antiseptic-impregnated catheters (chlorhexidine-silver sulfadiazine)
Number of subjects: 0
Study: 8747308

Group type: EXPERIMENTAL
Intervention: Trichlormethiazide (TCT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Nifedipine retard (NIF)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Atenolol (ATN)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Enalapril malate (ENP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 38
Study: 2117625

Group type: EXPERIMENTAL
Intervention: Ribavirin 1200 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ribavirin 1600 mg
Number of subjects: 16
Study: 6452805

Group type: EXPERIMENTAL
Intervention: Zimelidine (100 mg at night, increasing to 200 mg after two weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline (75 mg at night, increasing to 150 mg after two weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both zimelidine and amitriptyline
Number of subjects: 0
Study: 31604060

Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT) applied at 5 intraoral points for 30 seconds each on one side (laser group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no LLLT applied)
Number of subjects: 32
Study: 27865846

Group type: EXPERIMENTAL
Intervention: Educational physiotherapy home exercise intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 26507618

Group type: EXPERIMENTAL
Intervention: Fixed-Dose Combination (FDC) of aspirin and clopidogrel
Number of subjects: 93

Group type: COMPARATOR
Intervention: Separate Dual Pills (SDP) of aspirin and clopidogrel
Number of subjects: 93
Study: 23402546

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 180

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 180
Study: 21559284

Group type: EXPERIMENTAL
Intervention: Intravenous GH bolus
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous GH bolus plus an oral glucose load (OGTT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous saline plus OGTT
Number of subjects: 8
Study: 19264678

Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg daily
Number of subjects: 216

Group type: COMPARATOR
Intervention: Imatinib 400 mg daily
Number of subjects: 216

Group type: COMPARATOR
Intervention: Imatinib <350 mg daily
Number of subjects: 216
Study: 17692784

Group type: EXPERIMENTAL
Intervention: Gene expression profiling (GEP) testing
Number of subjects: 199

Group type: COMPARATOR
Intervention: Invasive endomyocardial biopsy (EMB)-based strategy
Number of subjects: 199
Study: 15138467

Group type: COMPARATOR
Intervention: D1 gastrectomy
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: D2 gastrectomy
Number of subjects: 118
Study: 11240262

Group type: EXPERIMENTAL
Intervention: Five-field segmented irradiation technique with a planned dose of 78 Gy.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Five-field segmented irradiation technique.
Number of subjects: 5

Group type: COMPARATOR
Intervention: Conventional three-field technique.
Number of subjects: 5
Study: 9825086

Group type: EXPERIMENTAL
Intervention: Evidence-based practice concepts
Number of subjects: 0
Study: 7811315

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 3041816

Group type: EXPERIMENTAL
Intervention: Cefoperazone plus tobramycin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Ticarcillin plus tobramycin
Number of subjects: 53
Study: 31081504

Group type: EXPERIMENTAL
Intervention: Nintendo WiiFit balance training, conducted twice a week for 3 months.
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 1016
Study: 28017593

Group type: EXPERIMENTAL
Intervention: Plain spinach
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Creamed spinach
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Spinach ravioli
Number of subjects: 103

Group type: COMPARATOR
Intervention: Green beans
Number of subjects: 103
Study: 25817200

Group type: EXPERIMENTAL
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: GlideScope‐assisted intubation (GS)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Supraglottic Airway Laryngopharyngeal Tube (SALT)
Number of subjects: 37
Study: 23564361

Group type: EXPERIMENTAL
Intervention: Manual circumlaryngeal therapy for 20 minutes
Number of subjects: 16

Group type: COMPARATOR
Intervention: Complete vocal rest for 20 minutes (Control)
Number of subjects: 16
Study: 21943153

Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 137

Group type: COMPARATOR
Intervention: Normal glucose tolerance
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 137

Group type: COMPARATOR
Intervention: Females
Number of subjects: 137
Study: 19283744

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (IPC)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no IPC)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Preconditioned serum in co-culture
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Post-RI serum co-culture
Number of subjects: 25
Study: 18173154

Group type: EXPERIMENTAL
Intervention: Zhixue Baotai Decoction (ZBD)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Progesterone
Number of subjects: 105
Study: 15106888

Group type: EXPERIMENTAL
Intervention: Young adults with a history of suicidal ideation or attempts responding to a hypothetical suicidal peer disclosure.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ambiguity of the suicidal disclosure.
Number of subjects: 0
Study: 12216436

Group type: EXPERIMENTAL
Intervention: Acidotic fetuses (pH < 7.20)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal fetuses (pH >= 7.20)
Number of subjects: 0
Study: 9467116

Group type: EXPERIMENTAL
Intervention: Sarin cases (acute sarin poisoning)
Number of subjects: 18
Study: 8551476

Group type: EXPERIMENTAL
Intervention: Amnioinfusion (300-500 mL bolus and 125-150 mL/h constant drip)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 68
Study: 1699835

Group type: EXPERIMENTAL
Intervention: IV albumin (8 g/L of ascitic fluid removed)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: IV dextran-70 (8 g/L of ascitic fluid removed)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 88
Study: 507789

Group type: EXPERIMENTAL
Intervention: Amoxicillin and probenecid
Number of subjects: 43

Group type: COMPARATOR
Intervention: Amoxicillin alone
Number of subjects: 43
Study: 29489484

Group type: EXPERIMENTAL
Intervention: 800-kcal, 20 g fat, and 70 g protein diet for 1 week before liver resection
Number of subjects: 60

Group type: COMPARATOR
Intervention: No special diet
Number of subjects: 60
Study: 28395171

Group type: EXPERIMENTAL
Intervention: Gait Variability Index (GVI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (implied)
Number of subjects: 100
Study: 26121998

Group type: EXPERIMENTAL
Intervention: Telephone-delivered multiple health behaviour change intervention using acceptance commitment therapy strategies
Number of subjects: 410

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Cost of delivering the intervention
Number of subjects: 410

Group type: COMPARATOR
Intervention: Health professional visits and medications
Number of subjects: 410
Study: 23540546

Group type: EXPERIMENTAL
Intervention: Early aggressive approach
Number of subjects: 645

Group type: COMPARATOR
Intervention: Initially conservative approach
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Independent predictors of all-cause death
Number of subjects: 645
Study: 21482566

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg iv every 12 h
Number of subjects: 613

Group type: COMPARATOR
Intervention: Ceftriaxone 1 g iv every 24 h
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 613

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 613
Study: 18953579

Group type: EXPERIMENTAL
Intervention: Mobile phone-based, remote monitoring, advanced symptom management system (ASyMS)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no ASyMS)
Number of subjects: 112
Study: 16398939

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 5) plus paclitaxel (175 mg/m2) every 3 weeks for 6 cycles
Number of subjects: 120
Study: 14988819

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors
Number of subjects: 11945
Study: 11335744

Group type: EXPERIMENTAL
Intervention: 22 kcal/fl oz nutrient-enriched postdischarge formula (PDF)
Number of subjects: 125

Group type: COMPARATOR
Intervention: 20 kcal/fl oz term-infant formula (TF)
Number of subjects: 125
Study: 9266288

Group type: EXPERIMENTAL
Intervention: fendol (test)
Number of subjects: 22

Group type: COMPARATOR
Intervention: ponstan (reference)
Number of subjects: 22
Study: 8281983

Group type: EXPERIMENTAL
Intervention: Low P:S high-saturated-fat diet (5% polyunsaturated fatty acids)
Number of subjects: 47

Group type: COMPARATOR
Intervention: High P:S high-linoleic-acid diet (21% polyunsaturated fatty acids)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 47
Study: 3427552

Group type: EXPERIMENTAL
Intervention: Prenylamine (PNL) 200 mg/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Adriamycin (ADM) at standard oncological doses up to 550 mg/m2 plus placebo
Number of subjects: 26
Study: 30371334

Group type: EXPERIMENTAL
Intervention: statin+niacin
Number of subjects: 2054

Group type: COMPARATOR
Intervention: statin+placebo
Number of subjects: 2054
Study: 27609676

Group type: EXPERIMENTAL
Intervention: Ganglion plexus (GP) ablation
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (no extra ablation)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 240